Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RevvityMEX:PKI 60 14-Day RSI is 99.99 as of Aug. 03, 2026. GuruFocus rates MEX:PKI with a GF Score™ of 60/100 and a GF Value™ of MXN2,214.93 (Modestly Undervalued). The stock has 11 warning signs investors should review. Among 216 Medical Diagnostics & Research companies, Revvity ranks worse than 73.61% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-08-03), Revvity's 14-Day RSI is 99.99.
The industry rank for Revvity's 14-Day RSI or its related term are showing as below:
MEX:PKI's 14-Day RSI is ranked worse than 73.61% of 216
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.02
vs MEX:PKI: 99.99
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Revvity 14-Day RSI Related Terms
MEX:PKI vs ICLR, CRL, QGEN: 14-Day RSI Comparison
For the Diagnostics & Research subindustry, Revvity's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revvity 14-Day RSI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Revvity's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Revvity's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revvity (MEX:PKI) has a 14-Day RSI of 99.99 as of Aug. 03, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Revvity and its competitors. According to the industry distribution chart, Revvity ranks #159 out of 216 companies in the Medical Diagnostics & Research industry, placing it in the top 73.6%.
Is Revvity's 14-Day RSI too high?
Revvity's current 14-Day RSI is 99.99. The Medical Diagnostics & Research industry median 14-Day RSI is 50.02. Revvity's value of 99.99 is 99.9% above this industry median. Based on the distribution chart, Revvity ranks #159 out of 216 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Revvity has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Revvity's 14-Day RSI compare to ICLR and CRL?
According to the Medical Diagnostics & Research industry distribution chart, Revvity ranks #159 out of 216 companies for 14-Day RSI. This places Revvity in the lower half of its industry. The industry median 14-Day RSI is 50.02. Revvity's value of 99.99 is 99.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Diagnostics & Research company?
The median 14-Day RSI among Medical Diagnostics & Research companies is 50.02, based on 216 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Revvity's current 14-Day RSI of 99.99 is 99.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Revvity and its competitors. For the Medical Diagnostics & Research industry, the median 14-Day RSI is 50.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revvity's current 14-Day RSI is 99.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revvity stock overvalued right now?
Based on GuruFocus' analysis, Revvity (MEX:PKI) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN2,214.93, compared to a current price of MXN1,910.00 — trading 13.8% below its estimated fair value. The current 14-Day RSI is 99.99 and 99.9% above the Medical Diagnostics & Research industry median of 50.02. Revvity's overall GF Score™ is 60/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Revvity (MEX:PKI), the current 14-Day RSI is 99.99 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revvity (MEX:PKI) Overvalued in 2026?
Based on GuruFocus' analysis, Revvity stock appears to be undervalued.
The current stock price of MXN1,910.00 is trading 13.8% below its estimated GF Value™ of MXN2,214.93.
GuruFocus considers Revvity to be Modestly Undervalued.
Key valuation signals for MEX:PKI:
14-Day RSI: 99.99
GF Value™: MXN2,214.93 vs. price of MXN1,910.00 (13.8% below fair value)
Industry Position: 99.9% above the Medical Diagnostics & Research median (#159 of 216)
No single metric tells the full story. See the MEX:PKI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
60GF Score
Get the complete analysis for MEX:PKI
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PKI has been successfully added to your 
